ICON Public Limited to Post FY2024 Earnings of $14.55 Per Share, Leerink Partnrs Forecasts (NASDAQ:ICLR)

ICON Public Limited (NASDAQ:ICLR) – Investment analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of ICON Public in a research report issued on Wednesday, September 18th. Leerink Partnrs analyst M. Cherny forecasts that the medical research company will post earnings per share of $14.55 for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $14.54 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2025 earnings at $16.64 EPS, FY2026 earnings at $18.67 EPS and FY2027 earnings at $20.60 EPS.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the firm earned $2.96 earnings per share. ICON Public’s revenue for the quarter was up 4.1% on a year-over-year basis.

Several other equities analysts have also recently weighed in on ICLR. Leerink Partners started coverage on shares of ICON Public in a research report on Wednesday, September 18th. They issued an “outperform” rating and a $379.00 price target on the stock. TD Cowen raised their target price on ICON Public from $349.00 to $373.00 and gave the company a “buy” rating in a report on Friday, May 31st. William Blair reiterated an “outperform” rating on shares of ICON Public in a report on Friday, May 31st. Robert W. Baird dropped their price objective on ICON Public from $368.00 to $340.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, The Goldman Sachs Group initiated coverage on shares of ICON Public in a research note on Thursday, June 6th. They issued a “buy” rating and a $370.00 target price for the company. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ICON Public presently has a consensus rating of “Buy” and a consensus price target of $351.60.

ICON Public Stock Down 2.2 %

ICON Public stock opened at $296.30 on Monday. The firm has a market capitalization of $24.44 billion, a price-to-earnings ratio of 36.05, a price-to-earnings-growth ratio of 1.29 and a beta of 1.22. The firm’s fifty day moving average price is $316.11 and its two-hundred day moving average price is $317.64. ICON Public has a 1-year low of $221.20 and a 1-year high of $347.72. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ICLR. Livelsberger Financial Advisory bought a new position in ICON Public during the fourth quarter valued at $29,000. Riverview Trust Co purchased a new stake in ICON Public in the 1st quarter worth about $31,000. Ashton Thomas Private Wealth LLC bought a new stake in ICON Public in the 2nd quarter valued at about $54,000. GAMMA Investing LLC increased its stake in shares of ICON Public by 22.5% in the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after purchasing an additional 32 shares in the last quarter. Finally, ORG Partners LLC bought a new stake in shares of ICON Public in the second quarter valued at approximately $59,000. 95.61% of the stock is owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.